Dutch medical-robotics company Microsure announced on May 7, 2026 that its MUSA-3 system has received CE mark approval under the European Union's Medical Device Regulation, clearing the platform for clinical use across Europe. The Eindhoven-based company also announced a leadership transition, with Alex Joseph stepping in as chief executive officer.
How MUSA-3 works
MUSA-3 is designed to assist surgeons during open super-microsurgical procedures by downscaling hand motions, filtering out tremor, and giving operators sub-millimeter precision on structures less than one millimeter in diameter. The system is purpose-built for super-micro-anastomosis on lymphatic ducts, small blood vessels and nerves, areas that are at the edge of human dexterity. Surgeons control the robot's instruments via a console while standing or seated at the operating table.
Why this is a milestone
Most surgical robots on the European market target abdominal, gynecological or thoracic procedures. MUSA-3 is the first commercially CE-marked platform aimed squarely at super-microsurgery, an indication that has historically depended on the steadiest human hands. The MDR mark also represents Microsure's transition from a clinical R&D program to a commercial business, opening the door to broader adoption in centers performing lymphedema treatment, free-flap reconstruction and nerve repair.
European regulatory tailwind
MUSA-3 joins a growing list of surgical robots winning European clearance in 2026, including the recently approved Cornerstone Robotics Sentire system and the Sentante endovascular platform. Together, the three approvals signal European notified bodies' increasing comfort with image-guided and robot-assisted devices under MDR.
Commercialization plan
Microsure said it will prioritize academic medical centers and major plastic, reconstructive and lymphatic-surgery programs in its initial European rollout, with evidence-generation studies designed to support future reimbursement. The company is also expanding its training and proctorship program for hospitals adopting the system.
Reporting based on coverage from PR Newswire, MedicalDevice-Network, Hospimedica and Microsure's official CE mark announcement.